Trial Profile

Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mevidalen (Primary)
Indications Parkinson's disease
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

01 Mar 2022 Results assessing pharmacodynamics (part B) were published in the Clinical Pharmacology in Drug Development.
20 Mar 2017 Status changed from active, no longer recruiting to completed.
24 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Feb 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com